https://orcid.org/0000-0002-5235-1203
Figures
Abstract
There are numerous uses for the pharmacological effects of thiazolo-pyridine and its derivatives. The main objective of the study was to synthesis 10 novel derivatives of thiazolo[3,2-a] pyridine-6,8-dicarbonitrile with a 22–78% yield, with a focus on their potential anti-diabetic properties. We investigated the interactions between these compounds and the enzyme α-amylase through an in silico study involving molecular docking. According to the docking analysis results, the resulting compounds had advantageous inhibitory properties. With a docking score of -7.43 kcal/mol against the target protein, compound 4e performed best. The stability root-mean-square deviation (RMSD) showed that the complex stabilizes after 25 ns and with minor perturbation at 80. The RMSF values of the ligand-protein complex indicate that the following residues have interacted with compound 4e during the MD simulation: Trp58, Trp59, Tyr62, Gln63, His101, Val107, lle148, Asn152, Leu162, Thr163, Gly164, Leu165, Asp197, Ala198, Asp 236, Leu237, His299, Asp300, and His305. Moreover, the pharmacokinetic and drug-like properties of the synthesized derivatives of 2-arylamino-dihydroindeno[1,2-b] pyrrol-4(1H)-one suggest that they have the potential to be effective inhibitors of α-amylase and should be considered for further research. Nevertheless, it is crucial to ascertain the in vivo and in vitro effectiveness of these compounds through biochemical and structural investigations.
Citation: Aghahosseini F, Bayat M, Sadeghian Z, Gheidari D, Safari F (2024) Synthesis, molecular docking study, MD simulation, ADMET, and drug likeness of new thiazolo[3,2-a]pyridine-6,8-dicarbonitrile derivatives as potential anti-diabetic agents. PLoS ONE 19(9): e0306973. https://doi.org/10.1371/journal.pone.0306973
Editor: Anjani Kumar Tiwari, Babasaheb Bhimrao Ambedkar University (A Central University), INDIA
Received: February 20, 2024; Accepted: June 25, 2024; Published: September 12, 2024
Copyright: © 2024 Aghahosseini et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All data generated or analyzed during this study are included in this published article and provided Supporting information file.
Funding: The author(s) received no specific funding for this work.
Competing interests: NO authors have competing interests.
Abbreviations: 2D, Two-dimensional; 3D, Three dimensional; Å, Angstroms; ADMET, Absorption, Distribution, Metabolism Excretion; BBB, Blood-brain barrier; CaCo-2, Human colon epithelial cancer cell line; CL, Clearance; CNS, Central nervous system; DMSO, Dimethyl sulfoxide; Et3N, Triethylamine; EtOH, Ethanol; FT-IR, Fourier transform infrared spectroscopy; GI, Gastrointestinal tract; HBA, Hydrogen bond acceptors; HBD, Hydrogen bond donors; HCl, Hydrochloric acid; hERG, Human ether-a-go-go-related gene; H-HT, Human hepatotoxicity; HIA, Human intestinal absorption; intra-HB, Intramolecular hydrogen bond; LD50, Median lethal dose; MD, Molecular dynamic; MDCK, Madin darby canine kidney; MHz, Megahertz; MolSA, Molecular surface area; MR, Molar refractivity; MW, Molecular weight; NMR, Nuclear magnetic resonance; NRB, Number of rotatable bonds; OH, Hydroxyl group; PAINS, Pan assay interference substances; PDB, Plasma protein binding; PGP, P-Glycoprotein; P-M, Poor-moderate; PSA, Polar surface area; rGyr, Radius of gyration; RMSD, Root-Mean-Square Deviation; RMSF, Root Mean Square Fluctuation; Ro5, Lipinski’s Rule of five; SA, Synthetic accessibility; SASA, Solvent accessible surface area; T1/2, Half-life; T2DM, Type 2 diabetes mellitus; TLC, Thin layer chromatography; TMS, Tetramethylsilane; TPSA, Topological polar surface area; VD, Volume of distribution; α-amylase, Alpha-amylase
1. Introduction
Diabetes mellitus is a long-term metabolic condition marked by increased levels of glucose in the bloodstream due to insufficient insulin production or utilization within the body [1, 2]. Sustained high blood sugar levels can give rise to numerous complications that significantly impact both physical well-being and overall quality of life [3]. T2DM is the predominant form of diabetes, making up around 85% to 90% of all diagnosed cases [4, 5]. Pancreatic α-amylase serves as a significant enzyme involved in starch breakdown within the small intestine. Its primary function is to break down dextrinized starch into maltose and various oligosaccharides by catalyzing the hydrolysis of the α-1,4-glucosidic bond. The subsequent digestion of the produced substances occurs through the action of other glucosidases [6]. A successful strategy to mitigate the effects of T2DM involves the inhibition of α-amylase in the gastrointestinal tract, leading to a delay in the digestion of starchy foods. This, in turn, effectively suppresses postprandial hyperglycemia and reduces its impact on individuals with T2DM. Studies have indicated that thiazolopyridines, which consist of two fused heterocyclic rings, exhibit inhibitory effects on enzymes associated with diabetes [7]. Due to the diverse biological properties of thiazolopyridine structures, they have garnered significant interest as promising synthetic targets, with numerous reports available in the literature. For instance, thiazolo[3,2-a]pyridin-8-yl-phosphonate, which serve as a representative of plant growth regulators, were synthesized by the reaction of diethyl (E)-(4-oxothiazolidin-2-ylidene)methyl)phosphonate, malononitrile, and aromatic aldehyde derivatives (Fig 1a). This work was reported by Altug et al. in 2019 [8]. Belal et al. developed the synthesis of thiazolo[3,2-a] pyridine-6,8-dicarbonitrile structures through a reaction of 2-chloro-quinoline-3-carbaldehyde, 2-(4-oxo-4,5-dihydrothiazol-2-yl)acetonitrile, malonitrile, and aromatic aldehydes in EtOH, in the presence of a catalytic amount of piperidine (Fig 1b) [9]. Kotthireddy et al. studied the formation of these structures using 2-(4-(2-oxo-2H-chromen-3-yl) thiazol-2-yl) acetonitrile as a crucial precursor. They revealed that target compounds can be obtained in a stepwise manner and a tandem method too (Fig 1c) [10]. Fettach et al. have shown that benzylidene-thiazolidinediones have inhibitory activity against α-amylase, with an IC50 value of 18.19 ± 0.11 μM [11]. In their 2022 study, Khan et al. discovered that thiazolidinone-based indole compounds had inhibitory effects on α-amylase, with an IC50 value of 1.80 ± 0.70 μM [12]. In another investigation, they showed that enzimidazoles containing thiazolidinone derivatives (IC50 value: 2.10 ± 0.10 μM) are α-amylase inhibitors [13]. Over the past decade, there has been a consistent increase in the rate of drugs failing in the later stages of clinical trials. This is because the assumptions developed for rational drug design, such as the idea of ’one drug, one gene, one disease’, were based on the belief that this approach would result in safer and more effective drugs. The goal was to design target-selective ligands that would eliminate undesirable side effects. Nevertheless, this idea has been consistently challenged throughout the last decade. The advancements in bioinformatics, polypharmacology, and network pharmacology have garnered interest as a cost-effective strategy for drug discovery, focusing on several targets simultaneously [14]. Alegaon et al. recently reported the synthesis of benzene sulphonamide-thiazolidin-4-one hybrids as promising efficacy against α-amylase inhibition with an IC50 value of 29.51±1.35 μg/ml [15]. Network pharmacology may improve knowledge of lead molecules and their interactions with targets, resulting in greater insights into the development of antidiabetic drugs. In order to induce a pharmacological response, structural modifications involving molecular framework modifications of compounds are required, according to the aforementioned research and literature. Herein, we carried out a one-pot, three-component process to synthesize a series of thiazolo[3,2-a]pyridine-6,8-dicarbonitrile derivatives (Fig 1d). By employing the molecular docking method, conducting ADMET analysis, and evaluating their drug-like characteristics, we have provided evidence of the inhibitory potential of these compounds against α-amylase.
2. Result and discussion
Synthesis
We synthesized a series of new functionalized thiazolo[3,2-a]pyridine-6,8-dicarbonitrile structures 4a–j by using thioglycolic acid 1, two equivalents of malononitrile 2, and various aromatic aldehydes 3a–j in absolute EtOH at reflux conditions (Fig 2).
The optimized reaction conditions were determined by using thioglycolic acid 1, two equivalents of malononitrile 2, and 4-chlorobenzaldehyde 3a as model substrates, in the presence of a piperidine catalyst. With the point of green chemistry, water solvent was tested in this reaction, but any product was not observed, neither at room temperature nor at the reflux condition (Table 1, entries 1–2). Then, EtOH was used, and the product was obtained after adding crushed ice and diluted HCl with a 52% yield (Table 1, entry 3). The product yield in the mixture of water / EtOH was very low (Table 1, entry 4). It was found that water or a ratio of water in the solvent mixture cannot proceed this reaction well. The reaction was conducted in absolute EtOH and resulted in a high yield without the need for any further purification processes (Table 1, entry 5). To obtain the best amount of piperidine as a catalyst, several percentages were tested (Table 1, entries 6–10). The efficiency of piperidine was confirmed by comparison with triethylamine as a catalyst in this work (Table 1, entry 11). According to these results, absolute EtOH at reflux and 50% piperidine were applied as optimized reaction conditions. Having obtained the most favorable reaction conditions, the procedure was expanded, resulting in the preparation of a range of thiazolo[3,2-a] pyridine-6,8-dicarbonitrile derivatives. Table 2 summarizes these results. Based on these results, it seems that the steric and electronic features of substitutes on the aromatic aldehyde ring play a role in this process and affect the product yield. For example, the highest product yield 4h was obtained when 4-nitrobenzaldehyde was used (78%). Clearly, the -NO2 group as an electron-withdrawing group makes the electrophile aldehyde moiety undergo a nucleophile such as malononitrile at the first step of this process. Using 4-dimethylaminobenzaldehyde led to the lowest product yield 4j. Obviously, -N(CH3)2 acts as an electron-donating group, which decreases the electrophilicity of the aldehyde moiety. Steric effects decrease the product yield in 4f and 4c in comparison with 4a. The presence of a -Cl substitute in the ortho position hinders a nucleophile attack, and there is more hinderance when two ortho positions are occupied with substitutes.
The possible mechanism reaction for synthesizing 4a is shown in Fig 3. First, the Knoevenagel condensation reaction of one equivalent 4-chlorobenzaldehyde 3a and malononitrile 2 leads to the formation of compound 5. Simultaneously, product 6 was formed through a cyclization reaction of thioglycolic acid and another equivalent of malononitrile 2. Then, this product undergoes another 4-chlorobenzaldehyde 3a reaction to obtain compound 7. Finally, the desired product 4a is formed by the nucleophilic addition of 7 to 5, followed by intramolecular cyclization.
Molecular docking studies
Molecular docking is the process of identifying appropriate ligands that can fit both geometrically and energetically into a protein’s active site. We utilized PDB code 4W93 [16] to perform molecular docking investigations of synthesized molecules with α-amylase, and the active site of α-amylase is shown in Supporting Information. The docking process was confirmed by re-docking the co-crystal ligand into the active pocket of the α-amylase. The RMSD value was below 2 Å, indicating the reliability of the docking procedure [17]. The active site of the protein was effectively targeted by docking potent thiazolo[3,2-a] pyridine-6,8-dicarbonitrile derivatives to essential amino acid residues. To assess the effectiveness of the synthesized derivatives, their binding affinities and binding scores were evaluated, employing the specific amino acid residues found in the active pocket. The affinity score was utilized to assess the strength of binding between the compounds. The findings revealed that all of the compounds exhibited robust binding scores and outstanding binding affinities. Notably, among these compounds, compound 4e displayed the highest binding energy, measured at -7.43 Kcal/mol. The best conformation of compound 4e was selected, and both bonding and non-bonding interactions were thoroughly analyzed. The docking outcomes of the potent compounds, along with their respective interactions, are presented in Table 3.
Fig 4 illustrates the detailed 3D and 2D interactions that compound 4e engages in within the active site of α-amylase. The amino acid residues Lys200, Asp300, His201, Ile235, Trp59, Leu162, Tyr151, Trp357, Thr163, His305, Ala198, Glu233, Asp197, His101, Trp58, His299, Tyr62, Leu165, and Gln63 play a role in forming both bonding and non-bonding interactions with compound 4e. In summary, compound 4e exhibits a total of three hydrogen bond interaction. Additionally, it plays a significant role in establishing ten hydrophobic contacts within the active site, encompassing four Alkyl interactions, five π-Alkyl, one π-Sigma interaction with specific amino acid residues. It also has a halogen interaction with specific amino acid residues. Moreover, Trp357, Thr163, His305, Ala198, Glu233, Asp197, His101, Trp58, His299, Tyr62, Leu165, and Gln63 were the specific amino acid residues involved in the van der Waals interaction with compound 4e.
MD simulation
The results of molecular docking studies, although somewhat suggestive of the real process of protein-ligand binding, are further elucidated by MD simulations, which provide a comprehensive understanding of the interactions, including even the subtlest differences. Consequently, a MD simulation was conducted to investigate the best protein-ligand complex over a duration of 100 ns, with the aim of uncovering precise atomic-level information about molecular interactions (Fig 5). The RMSD study of the Cα atoms revealed that the complex stabilizes after 25 nanoseconds and stays stable with slight perturbation at 80. RMSD, with respect to its initial position, rose to 2.30 for the initial 25 ns before becoming more stable thereafter. All of these RMSDs are within acceptable ranges, indicating that values remained stable in the receptor-ligand complex during the simulation.
The RMSF feature reveals the receptor’s average deviation from the reference position. Fig 6 depicts a complete examination of compound 4e’s interaction with the residues of the α-amylase binding site. The residues that interact with compound 4e are as follows: Trp58, Trp59, Tyr62, Gln63, His101, Val107, lle148, Asn152, Leu162, Thr163, Gly164, Leu165, Asp197, Ala198, Asp 236, Leu237, His299, Asp300, and His305. The values for the residues inside the binding site were determined to be less than 2 Å. The residue that interacts with compound 4e is shown in the color green. The graphic displays the protein’s secondary structures, with helices represented by orange bands and β-strands represented by blue bands.
During the 100 ns the compound 4e mostly established non-covalent interactions with the amino acids Asp300, Tyr62, Gln63, and Gly164. The Fig 7 illustrate the various types of non-covalent interactions involving these amino acids, such as hydrogen bonding, hydrophobic interactions, ionic interactions, and water bridge formation. Additionally, the figures demonstrate the individual contributions of each interaction type to the overall interaction with a specific amino acid.
A: Schematic of detailed ligand atom interactions with the protein residues. B: Protein–ligand contacts.
Fig 8 displays the time-dependent overall number of interactions between the ligand and protein, as well as the number of interactions specifically between the ligand and amino acids. The upper panel displays the overall number of contacts made by compound 4e with the binding site of α-amylase along the whole journey, while the lower panel illustrates the specific interactions occurring at each residue. The residues Trp59, Tyr62, Gln63, and Tyr151 exhibited consistent interactions across all frames.
The ligand properties were examined throughout the 100-ns MD simulation and are shown in Fig 9. The RMSD of a ligand with respect to its reference conformation (t = 0) was calculated to be between 0.1 and 3.9 Å. The rGyr predicts the firmness of ligand-protein complex within the range of 4.1 to 6 Å. The presence of an intra-HB was identified. The MolSA was calculated by measuring the van der Waals surface area within the range of 419 to 431 Å. The SASA analysis measures the extent of interaction between a ligand and solvents across a 100-ns MD simulation. The resulting values range from 90 to 320 Å. The PSA, which offers insights into the solvent’s capacity to reach the surface area defined by oxygen and nitrogen atoms, The PSA value varied between 158 and 210 Å.
In silico drug-likeness prediction
Drug-likeness prediction is important in drug discovery and development because it allows researchers to choose compounds for further investigation while also reducing the time and expenses associated with the drug development process. The procedure entails analyzing many physical and chemical characteristics of a molecule, including its molecular weight, lipophilicity, hydrogen bonding capability, and solubility. Lipinski’s rule, popularly known as the "Ro5," is a widely used approach for estimating the suitability of a molecule as a drug. According to this rule, compounds that fail to meet certain requirements are more likely to have inadequate absorption or penetration. These criteria include having more than 5 HBD combining NH and OH groups, a molecular weight exceeding 500, a Log P value above 5, and more than 10 HBA including N and O atoms [18]. We examined all of our derivatives using the SwissADME [19] online web server. Our analysis revealed that all thiazolo[3,2-a] pyridine-6,8-dicarbonitrile derivatives adhere to the Ro5, meaning that they do not have more than one violation. Consequently, there should be no concerns regarding their oral bioavailability. The pharmacokinetic parameters indicated that the studied compounds 4a, 4d, 4f, and 4j are rapidly absorbed via the GI after oral intake. Other metrics, such as molecular weight, HBD, HBA, and rotatable bonds, are within our synthesized compounds’ range, suggesting that they might easily traverse cell membranes. The Brenk and PAINS structural warnings have been utilized in pharmaceutical chemistry to determine whether sections of the structure are unstable, reactive, and dangerous [20, 21]. Except for compound 4b, 4h, which contained two nitro_groups and an oxygen-nitrogen_single_bond, all of the compounds had adequate Brenk descriptions. Furthermore, with the exception of compound 4j, which had an anil_di_alk_B warning, all of the compounds had strong PAINS descriptions, indicating that they might be potential drug prospects. The SA score is a measure used to assess the ease of synthesizing drug-like molecules; all of the compounds have a favorable SA value, suggesting that they can be easily synthesized, as shown in Table 4.
In silico ADMET properties
ADMET properties play a crucial role in the early stages of drug discovery and development. Computational models have been developed to evaluate ADMET features, such as absorption, distribution, metabolism, and toxicity, for the purpose of drug design and lead optimisation. These models use ADMET lab 2.0 [22]. This integrated online platform offers a reliable and extensive means to accurately predict and assess ADMET properties. The considered ADMET profile includes various factors such as physicochemical properties, BBB permeability, Caco-2 permeability, VD, PGP substrate, HIA, MDCK permeability, CL, T1/2, potential for eye corrosion, eye irritation, respiratory toxicity, AMES toxicity, carcinogenicity, and synthetic accessibility score. CaCo-2 cells, which are derived from human colon epithelial cells, are widely utilized as a model system to assess the ability of drugs to be absorbed in the human intestines. In contrast, MDCK cells, known for their shorter growth cycle compared to CaCo-2 cells, are valuable for evaluating the rapid permeability of drug molecules [23]. The obtained results of CaCo-2 cell permeability for our synthesized compounds demonstrated values within a desirable range, indicating that these compounds exhibit excellent intestinal absorption capabilities. Furthermore, all the compounds exhibited favourable MDCK cell permeability, indicating a higher likelihood of elimination through kidney cells. The results also indicated that all the compounds, except compound 4j, displayed characteristics that suggest they are substrates for PGP. To elaborate further, compounds 4b, 4c, 4f, 4g, 4h, and 4i have been identified as inhibitors of PGP, whereas compounds 4a, 4d, 4e, and 4j do not exhibit inhibitory effects on PGP. Considering the HIA values, it can be concluded that all the compounds possess a favourable probability of being absorbed through the intestinal membrane. The predictions for efflux values indicate that all compounds have the potential to penetrate the BBB, and among them, compound 4i exhibits the lowest BBB value. The involvement of the OH in hydrogen bonding is evident, as it ultimately results in a decrease in the compound’s ability to penetrate the BBB. These findings align well with the study conducted by Young et al., which demonstrated that excessive hydrogen bonding limits the penetration of antihistamines into the CNS [24]. The percentage representation of the plasma protein binding model indicates the degree to which a compound strongly binds to carrier proteins in the blood. The plasma protein binding values for all the compounds surpass 94%, indicating that our synthesized thiazolo[3,2-a] pyridine-6,8-dicarbonitrile derivatives possess ample bioavailability and are unlikely to demonstrate significant binding to carrier proteins in the blood. Cytochrome P450 is a heme-containing enzyme that is found on the lipid bilayer of the endoplasmic reticulum of hepatocytes, where the majority of drug, steroid, and carcinogen metabolism occurs [25]. CYP P450 has two main subtypes: CYP2D6 and CYP3A4. The findings demonstrated negative inhibitory capacity for CYP2D6 enzymes, indicating that it is safe for pharmacokinetic interactions. Regarding carcinogenicity, compounds 4b, 4h, and 4j were determined to be non-carcinogenic, while compounds 4d and 4g do not exhibit a clear classification as either carcinogenic or non-carcinogenic. On the other hand, the other compounds have a likelihood of being carcinogenic. The AMES toxicity assessment revealed that compounds 4b, 4d, 4g, 4h, and 4j are non-AMES toxic, while compounds 4c and 4f do not exhibit a clear classification as either AMES or non-AMES toxic. However, the other compounds have a probability of being toxic. Overall, all the compounds demonstrated a favourable ADMET profile. All values are tabulated in Table 5.
3. Conclusion
A series of thiazolo[3,2-a] pyridine-6,8-dicarbonitrile derivatives were prepared based on the reaction of thioglycolic acid, malononitrile, and aromatic aldehyde derivatives in absolute EtOH at reflux conditions, and all of the compounds were investigated for in silico study. During the docking, we successfully docked all of the compounds with the enzyme α-amylase. Our results indicate that all of the compounds have many potential inhibitors. Notably, compound 4e exhibited a strong binding affinity with the α-amylase. The stability, RMSD, and RMSF values of the ligand-protein complex for 4e were assessed by MD simulation, and outcome of docking was confirmed using MD simulation. The pharmacokinetic and drug-like properties of thiazolo[3,2-a] pyridine-6,8-dicarbonitrile derivatives are valuable and provide an informative and promising investigation as effective α-amylase inhibitors. The findings of the chemoinformatics study would need to be validated by more in vivo and in vitro research.
4. Experimental
General
All compounds were obtained from Merck and Aldrich chemical companies. The melting points were measured using an Electro-thermal 9100. The FT-IR spectra were taken using KBr discs on a Bruker tensor 27 spectrometer, with absorbencies reported in cm−1. The NMR spectra were recorded with a Bruker DRX-400 AVANCE instrument (400 MHz for 1H and 100 MHz for 13C) with deuterated dimethyl sulfoxide (DMSO-d6) as solvent and tetramethylsilane (TMS) as an internal standard. Chemical shifts are given in ppm (δ) and coupling constant (J) is reported in Hertz (Hz).
General method to synthesis thiazolo[3,2-a]pyridine-6,8-dicarbonitrile (4a–j)
A mixture of thioglycolic acid 1 (1 mmol), malononitrile 2 (2 mmol) aldehydes 3 (2 mmol) in the presence of piperidine (50 mol%) was heated in EtOH (5 mL) at reflux condition. After appropriate time, yellow precipitate was formed (monitored by TLC). After confirming the completion of the reaction using TLC, the solid product was filtered and washed to get the pure product.
Selected spectral data
(Z)-5-amino-2-(4-chlorobenzylidene)-7-(4-chlorophenyl)-3-oxo-3,7-dihydro-2H-thiazolo[3,2-a]pyridine-6,8-dicarbonitrile (4a): Yellow solid; yield: (56%); mp: 265–267°C; IR (KBr) (νmax /cm-1): 3378, 3282, 2202, 1717, 1654, 1560, 1409, 1333, 1155, 1092, 772; 1H NMR (400 MHz, DMSO-d6): δ 4.58 (1H, s, CH), 7.37 (4H, br, Ar-H), 7.49 (2H, s, NH2), 7.55 (2H, d, J = 6.0 Hz, ArH), 7.59 (2H, d, J = 9.0 Hz, ArH), 7.76 (1H, s, CH); 13C{1H} NMR (100 MHz, DMSO-d6): δ 40.2 (CH), 63.2 (CCN), 87.3 (CCN), 115.7 (CN), 118.5 (CN), 119.5 (CH = C-S), 128.8, 129.6, 130.0 (Ar), 130.4 (C-Cl), 131.6 (CH = C-S), 131.8, 132.7 (Ar), 135.1 (C-Cl), 140.7 (= CH), 143.0 (C = C-CN), 147.9 (NC = O), 165.2 (= C-NH2).
(Z)-5-amino-2-(2-nitrobenzylidene)-7-(2-nitrophenyl)-3-oxo-3,7-dihydro-2H-thiazolo[3,2-a]pyridine-6,8-dicarbonitrile (4b): Light brown solid; yield: (46%); mp: 236–238°C; IR (KBr) (νmax /cm-1): 3393, 3299, 2199, 1721, 1654, 1563, 1524, 1412, 1333, 1258, 1169, 867, 781; 1H NMR (400 MHz, DMSO-d6): δ 5.08 (1H, s, CH), 7.52–7.89 (8H, m, Ar-H), 8.00 (1H, s, CHvinyl), 8.14 (2H, s, NH2); 13C{1H} NMR (100 MHz, DMSO-d6): δ 36.1 (CH), 62.5 (CCN), 86.5 (CCN), 115.3 (CN), 118.1 (CN), 123.3 (CH = C-S), 124.2, 125.7, 128.3, 128.6, 128.8, 129.7, 131.3, 132.0, 134.0, 135.0, 143.9 (C = C-CN), 147.7 (C-NO2), 148.2 (NC = O), 148.5 (C-NO2), 164.4 (= C-NH2).
(Z)-5-amino-2-(2,6-dichlorobenzylidene)-7-(2,6-dichlorophenyl)-3-oxo-3,7-dihydro-2H-thiazolo[3,2-a]pyridine-6,8-dicarbonitrile (4c): Yellow solid; yield: (44%); mp: 299–301°C; IR (KBr) (νmax /cm-1): 3420, 3330, 2200, 1719, 1650, 1562, 1422, 1333, 1257, 1155, 856, 778; 1H NMR (400 MHz, DMSO-d6): δ 5.46 (1H, s, CH), 7.31–7.57 (6H, m, Ar-H and 2H, s, NH2), 7.76 (1H, s, CH); 13C{1H} NMR (100 MHz, DMSO-d6): δ 37.5 (CH), 59.9 (CCN), 84.9 (CCN), 114.8 (CN), 117.7 (CN), 126.8 (CH = C-S), 128.1, 128.9, 128.9, 130.6, 130.9, 131.1, 132.2, 132.4, 133.0, 134.9, 135.6, 143.6 (C = C-CN), 149.0 (NC = O), 163.4 (= C-NH2).
(Z)-5-amino-2-(4-fluorobenzylidene)-7-(4-fluorophenyl)-3-oxo-3,7-dihydro-2H-thiazolo[3,2-a]pyridine-6,8-dicarbonitrile (4d): Yellow solid; yield: (35%); mp: 267–269°C; IR (KBr) (νmax /cm-1): 3381, 3283, 2199, 1721, 1656, 1604, 1561, 1507, 1414, 1335, 1234, 1155, 827; 1H NMR (400 MHz, DMSO-d6): δ 4.56 (1H, s, CH), 7.11–7.17 (2H, m, Ar-H), 7.29–7.37 (4H, m, Ar-H), 7.46 (2H, br s, Ar-H), 7.64 (2H, s, NH2), 7.77 (1H, s, CH); 13C{1H} NMR (100 MHz, DMSO-d6): δ 40.1 (CH), 63.5 (CCN), 87.5 (CCN), 115.5 (CN), 115.7 (Ar), 115.8 (Ar), 116.6 (CN), 116.8 (CH = C-S), 118.4, 118.4, 118.6, 129.4, 129.5, 130.2, 130.2, 130.6, 132.6, 132.7, 138.0, 138.0, 142.8 (C = C-CN), 147.8 (NC = O), 160.5, 161.6, 162.9, 164.1, 165.3 (= C-NH2).
(Z)-5-amino-2-(2-chlorobenzylidene)-7-(2-chlorophenyl)-3-oxo-3,7-dihydro-2H-thiazolo[3,2-a]pyridine-6,8-dicarbonitrile (4f): Green solid; yield: (30%); mp: 296–298°C; IR (KBr) (νmax /cm-1): 3388, 3285, 2199, 1716, 1651, 1561, 1410, 1332, 1152, 1044, 755; 1H NMR (400 MHz, DMSO-d6): δ 4.99 (1H, s, CH), 7.25–7.60 (8H, m, Ar-H and 2H, s, NH2), 7.87 (1H, s, CH); 13C{1H} NMR (100 MHz, DMSO-d6): δ 38.2 (CH), 62.3 (CCN), 86.8 (CCN), 115.4 (CN), 118.2 (CN), 122.3 (CH = C-S), 126.5, 128.1, 128.4, 128.9, 129.7, 129.9, 130.5, 130.5, 131.4, 132.1, 132.2, 134.3, 138.0, 143.4 (C = C-CN), 148.2 (NC = O), 164.8 (= C-NH2).
(Z)-5-amino-2-(4-nitrobenzylidene)-7-(4-nitrophenyl)-3-oxo-3,7-dihydro-2H-thiazolo[3,2-a]pyridine-6,8-dicarbonitrile (4h): Brown solid; yield: (53%); mp: 240–242°C; IR (KBr) (νmax /cm-1): 3374, 3272, 2203, 1719, 1650, 1566, 1516, 1414, 1341, 1158, 845, 708; 1H NMR (400 MHz, DMSO-d6): δ 4.82 (1H, s, CH), 7.57 (2H, s, NH2), 7.65 (2H, d, Ar-H, J = 9.0 Hz), 7.83 (2H, d, Ar-H, J = 9.0 Hz), 7.89 (1H, s, CH), 8.19 (2H, d, Ar-H, J = 9.0 Hz), 8.28 (2H, d, Ar-H, J = 9.0 Hz); 13C{1H} NMR (100 MHz, DMSO-d6): δ 40.4 (CH), 62.5 (CCN), 87.1 (CCN), 115.5 (CN), 118.3 (CN), 123.2 (CH = C-S), 124.1, 124.5 129.1, 129.6, 131.1, 138.9, 143.5 (C = C-CN), 147.3, 147.4, 148.1, 148.7 (NC = O), 164.9 (= C-NH2).
Computational studies
Molecular docking.
The α-amylase enzyme’s interaction with synthesized compounds was studied using Schrodinger’s Maestro Molecular Modelling platform. The protein 3D structure was obtained from PDB (4W93) [16]. Protein was prepared using the Protein Preparation Wizard [26], and missing residues were modified. Using the ligprep module, compounds were optimized. The OPLS_2005 force field was used to prepare the ligand at pH 7.0± 2 [27]. With standard accuracy and flexible ligand sampling, Glide makes 26-A grid boxes at each binding site and reports 10 poses for each ligand.
Molecular dynamic simulation.
Desmond was used for MD simulation via Schrödinger-Maestro [28]. The MD simulation conducted on the complex after the docking process produced the results. The SPC model cells exhibited an orthorhombic structure and were completely filled by water. The charge of the complex was equilibrated by introducing a sufficient quantity of Na ions. The simulation had a duration of 100 nanoseconds. The NPT ensemble was used to maintain a fixed number of atoms, a pressure of 1.01325 bar, and a temperature of 300 K. The first thermostat and barostat used in the system were the 1.0‐ps Nose-Hoover chain and 2.0‐ps Martyna-Tobias-Klein techniques, respectively. The MD simulation was assessed using the maestro simulation interaction diagram.
Supporting information
S1 File. The supporting information is available and provided copies of IR, 1H NMR and 13C NMR spectra for all products.
https://doi.org/10.1371/journal.pone.0306973.s001
(DOCX)
Acknowledgments
This work was supported by Imam Khomeini International University and University of Guilan, Iran.
References
- 1. Kaur N., Kumar V., Nayak S.K., Wadhwa P., Kaur P., Sahu S.K. (2021). Alpha-amylase as Molecular Target for Treatment of Diabetes Mellitus: A Comprehensive Review. Chemical Biology & Drug Design, 98, 539–560. pmid:34173346
- 2. Ning C., Jiao Y., Wang Y., Li W., Zhou J., Lee Y.C., et al. (2022). Recent advances in the managements of type 2 diabetes mellitus and natural hypoglycemic substances. Food Science and Human Wellness,11,1121–1133.
- 3. Chand S., Tripathi A.S., Dewani A.P., Sheikh N.W.A.(2024). Molecular targets for management of diabetes: Remodelling of white adipose to brown adipose tissue, Life Sciences,345,15, 122607. pmid:38583857
- 4. American Diabetes Association Professional Practice Committee. (2022). Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022;45(Supplement_1):S17–S38.
- 5. Danaei G., Finucane M.M., Lu Y., Singh G.M., Cowan M.J., Paciorek C.J., et al. (2011). Stevens, G.A. National, Regional, and Global Trends in Fasting Plasma Glucose and Diabetes Prevalence since 1980: Systematic Analysis of Health Examination Surveys and Epidemiological Studies with 370 Country-Years and 2·7 Million Participants. Lancet, 378, 31–40.
- 6. Dona A.C., Pages G., Gilbert R.G., Kuchel P.W. (2010). Digestion of Starch: In Vivo and in Vitro Kinetic Models Used to Characterise Oligosaccharide or Glucose Release. Carbohydrate Polymers, 80, 599–617.
- 7. Park H., Hwang K. Y., Oh K. H., Kim Y. H., Lee J. Y., & Kim K. (2008). Discovery of novel α-glucosidase inhibitors based on the virtual screening with the homology-modeled protein structure. Bioorganic & medicinal chemistry, 16(1), 284–292.
- 8. Altuğ C., Yakubu Saleh L., Caner E., Güneş H., & Sameeullah M. (2019). Multicomponent synthesis of novel thiazolo [3, 2-a] pyridin-8-yl-phosphonates as a model of plant growth regulator. Phosphorus, Sulfur, and Silicon and the Related Elements, 194(1–2), 111–119.
- 9. Selim M. R., Zahran M. A., Belal A., Abusaif M. S., Shedid S. A., Mehany A., et al. (2019). Hybridized quinoline derivatives as anticancer agents: design, synthesis, biological evaluation and molecular docking. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 19(4), 439–452. pmid:30417798
- 10. Kotthireddy K., Devulapally S., Dubey P. K., & Pasula A. (2019). An Efficient One‐pot Three‐component Method for the Synthesis of 5‐Amino‐3‐(2‐oxo‐2H‐chromen‐3‐yl)‐7‐aryl‐7H‐thiazolo [3, 2‐a] pyridine‐6, 8‐dicarbonitriles. Journal of Heterocyclic Chemistry, 56(3), 938–946.
- 11. Fettach S., Thari F.Z., Hafidi Z., Tachallait H., Karrouchi K., El achouri M., et al. (2022). Synthesis, α-glucosidase and α-amylase inhibitory activities, acute toxicity and molecular docking studies of thiazolidine-2,4-diones derivatives. Journal of Biomolecular Structure and Dynamics, 40(18), 8340–8351.
- 12. Khan S., Iqbal S., Rahim F., Shah M., Hussain R., Alrbyawi H., et al. (2022). New Biologically Hybrid Pharmacophore Thiazolidinone-Based Indole Derivatives: Synthesis, In Vitro Αlpha-Amylase and Αlpha-Glucosidase Along with Molecular Docking Investigations. Molecules,27(19):6564.
- 13. Khan S., Ullah H., Rahim ., Nawaz ., Hussain ., Rasheed . (2022). Synthesis, in vitro α-amylase, α-glucosidase activities and molecular docking study of new benzimidazole bearing thiazolidinone derivatives. Journal of Molecular Structure, 1269, 133812.
- 14. Li S., Zhang B. (2013). Traditional Chinese medicine network pharmacology: theory, methodology and application. Chinese Journal of Natural Medicines, 11 (2), 110–120. pmid:23787177
- 15. Ranade S.D.,. Alegaon S.G., Khatib N.A., Gharge S., Kavalapure R.S., Kumar B.R.P.(2024). Design, synthesis, molecular dynamic simulation, DFT analysis, computational pharmacology and decoding the antidiabetic molecular mechanism of sulphonamide-thiazolidin-4-one hybrids. Journal of Molecular Structure 1311,138359.
- 16.
https://www.rcsb.org
- 17. Gheidari D., Mehrdad M., Bayat M. (2023). Synthesis, Molecular Docking, MD Simulation, ADMET, Drug Likeness, and DFT Studies of Novel Furo [2,3-b] indol-3a-ol as promising Cyclin-dependent kinase 2 inhibitors. Scientific Reports 14, 3084
- 18. Lipinski C.A.; Lombardo F.; Dominy B.W., Feeney P.J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23, 3–25.
- 19. Daina A., Michielin O., Zoete V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. pmid:28256516
- 20. Brenk R., Schipani A., James D., Krasowski A., Gilbert I.H., Frearson J., et al. (2008). Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem, 3, 435–444. pmid:18064617
- 21. Baell J.B., Holloway G.A. (2010). New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. Journal of Medicinal Chemistry, 53, 2719–2740. pmid:20131845
- 22.
ADMETlab 2.0, https://admetmesh.scbdd.com/, accessed 29 September 2021.
- 23. Rodic M. R., Leovac V. M., Jovanovic L. S., et al. (2016). Synthesis, characterization, cytotoxicity and antiangiogenic activity of copper (II) complexes with 1-adamantoyl hydrazone bearing pyridine rings European Journal of Medicinal Chemistry 115, 75–81.
- 24. Young R.C., Mitchell R.C., Brown T.H., Ganellin C.R., Griffiths R., Jones M., et al. (1988). Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. Journal of Medicinal Chemistry, 31, 656–671. pmid:2894467
- 25. Guengerich F.P., Wilkey C.J., Phan T.T.N. (2019). Human cytochrome P450 enzymes bind drugs and other substrates mainly through conformational-selection modes. J. Biol. Chem. 294 (28), 10928–10941 pmid:31147443
- 26.
Protein Preparation Wizard. Schrödinger Suite 2017–1: Protein Preparation Wizard. New York: Schrödinger, LLC; 2017.
- 27.
LigPrep. Schrödinger Release 2017–1: LigPrep. New York: Schrödinger, LLC; 2017.
- 28.
Desmond. Schrödinger Release 2017–1: Desmond. New York: Schrödinger, LLC; 2017.